| References: |
YO-01027 (Dibenzazepine, DBZ) is a dipeptidic g-secretase inhibitor with IC50 of 2.6 and 2.9 nM for APPL and Notch, respectively. YO-01027 targets the Presenilin fragment. Increasing concentrations of YO-01027 administered to APPl- or Notch-expressing cells leads to the progressive accumulation of APPL C-terminal fragments and a decrease in NICD production in a dose-dependent manner.
In an in vitro model of human corneal and conjunctival epithelial cell differentation, YO-01027 impaired MUC16 biosynthesis in a concentration-dependent manner.
In oncology models, YO-01027 preferentially inhibited Notch and significantly decreased MCF7 tumors and increased latency compared with control mice. For the detailed information of YO-01027(Dibenzazepine) , the solubility of YO-01027(Dibenzazepine) in water, the solubility of YO-01027(Dibenzazepine) in DMSO, the solubility of YO-01027(Dibenzazepine) in PBS buffer, the animal experiment (test) of YO-01027(Dibenzazepine) , the cell expriment (test) of YO-01027(Dibenzazepine) , the in vivo, in vitro and clinical trial test of YO-01027(Dibenzazepine) , the EC50, IC50,and affinity,of YO-01027(Dibenzazepine) , For the detailed information of YO-01027(Dibenzazepine) , the solubility of YO-01027(Dibenzazepine) in water, the solubility of YO-01027(Dibenzazepine) in DMSO, the solubility of YO-01027(Dibenzazepine) in PBS buffer, the animal experiment (test) of YO-01027(Dibenzazepine) , the cell expriment (test) of YO-01027(Dibenzazepine) , the in vivo, in vitro and clinical trial test of YO-01027(Dibenzazepine) , the EC50, IC50,and affinity,of YO-01027(Dibenzazepine) , Please contact DC Chemicals. |
